Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUST: +61 294230881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
5
Stocks News & Analysis
stocks
Are ASX REITs the better way to own property?
Cheap valuations, strong yields and a changing Aussie property landscape.
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,279.00 | 3.00 | -0.03% |
| CAC 40 | 8,579.60 | 57.19 | -0.66% |
| DAX 40 | 26,338.61 | 101.70 | -0.38% |
| Dow JONES (US) | 53,459.78 | 272.63 | -0.51% |
| FTSE 100 | 10,720.30 | 29.81 | -0.28% |
| HKSE | 25,453.23 | 336.38 | 1.34% |
| NASDAQ | 26,644.91 | 84.25 | -0.32% |
| Nikkei 225 | 69,220.25 | 506.45 | 0.74% |
| NZX 50 Index | 13,745.31 | 23.33 | 0.17% |
| S&P 500 | 7,745.06 | 40.70 | -0.52% |
| S&P/ASX 200 | 9,073.20 | 6.10 | -0.07% |
| SSE Composite Index | 3,982.65 | 55.48 | 1.41% |